Abstract
Human papillomaviruses are associated with a broad range of carcinomas, including cervical cancer. Although the delivery of immunogenic tumor-associated antigens represents a promising approach in the treatment of these malignancies, the imposition of T cell tolerance poses a significant challenge in this endeavor. The purpose of this review is to discuss T cell tolerance and the role of T cell costimulation in the immunotherapy of HPV-associated malignancies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Animals
-
Antigens, CD
-
Cancer Vaccines
-
Dendritic Cells / transplantation
-
Female
-
Humans
-
Immune Tolerance*
-
Lymphocyte Activation
-
Mice
-
Papillomaviridae*
-
Papillomavirus Infections / immunology
-
Papillomavirus Infections / therapy*
-
Receptors, Nerve Growth Factor / metabolism
-
Receptors, Tumor Necrosis Factor / metabolism
-
T-Lymphocytes / immunology
-
Tumor Necrosis Factor Receptor Superfamily, Member 9
-
Tumor Virus Infections / immunology
-
Tumor Virus Infections / therapy*
-
Uterine Cervical Neoplasms / immunology
-
Uterine Cervical Neoplasms / virology
Substances
-
Antigens, CD
-
Cancer Vaccines
-
Receptors, Nerve Growth Factor
-
Receptors, Tumor Necrosis Factor
-
TNFRSF9 protein, human
-
Tnfrsf9 protein, mouse
-
Tumor Necrosis Factor Receptor Superfamily, Member 9